SCHEDULE: Adage Capital Management Acquires 7.67% Stake in NextCure

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 7.67% of NextCure, Inc.'s common stock as of June 30, 2026.

Summary

• Adage Capital Management, L.P. (ACM), along with its affiliates Robert Atchinson and Phillip Gross, has filed a Schedule 13G.
• This filing indicates beneficial ownership of 277,202 shares of NextCure, Inc. common stock.
• This ownership represents 7.67% of the company's outstanding common stock as of May 1, 2026.
• The filing is made by ACM as the investment manager for Adage Capital Partners, L.P. (ACP), which directly holds the shares.
• Robert Atchinson and Phillip Gross are identified as managing members of entities that manage ACM and ACP.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake acquired by an investment manager, without immediate implications for company control or strategy.

Positives

• Significant investment by a known investment manager (Adage Capital Management) suggests confidence in NextCure's potential.
• The acquisition of a 7.67% stake indicates a substantial belief in the company's value or future prospects.

Negatives

• The filing does not provide specific reasons for the acquisition, leaving the strategic intent open to interpretation.
• The passive nature of the Schedule 13G filing suggests the investment is not intended to influence control, which might limit immediate positive impact on corporate strategy.

Risks

• Market volatility could impact the value of the acquired stake.
• Changes in investment strategy by Adage Capital Management could lead to future sales of shares.
• The company's ongoing clinical trials and regulatory approvals present inherent risks to its future performance.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from NextCure. It is a disclosure of beneficial ownership by an investment manager.

Management Comments

• "The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by an investment manager like Adage Capital Management in a biotechnology company like NextCure is common. Such filings often precede or coincide with shifts in investor sentiment or strategic evaluations of the company's pipeline and market position.

Stakeholder Impact

• Shareholders: May view the investment by Adage Capital Management as a positive signal, potentially increasing demand for shares.
• Management: May face increased scrutiny or engagement from a significant institutional investor.
• Creditors: Unlikely to be directly impacted in the short term by this ownership filing.

Next Steps

• Monitor future filings from Adage Capital Management for any changes in their stake.
• Observe NextCure's operational and clinical developments for potential impact on investor interest.

Key Dates

Keywords

NextCure, Schedule 13G, Adage Capital Management, Investment, Beneficial Ownership, Common Stock, SEC Filing, Healthcare